Scioderm

Dec 04, 2019

FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

Jan 22, 2019

TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of-Concept Study of AC-203 for Treatment of Epidermolysis Bullosa

Jan 04, 2019

RegeneRx Update on Dry Eye and EB Clinical Trials

Nov 27, 2018

Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)

Oct 29, 2018

RegeneRx Partner Updates on Clinical Trials

Jun 25, 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

May 16, 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

Apr 24, 2018

ARANZ Medical's pedigree in clinical trials makes Silhouette(R) the obvious choice for new research

Feb 26, 2018

TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa

Oct 27, 2017

BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa (EB)

Oct 12, 2017

Epidermolysis Bullosa - Pipeline Review, H2 2017